Erin Finot

Sep 18, 2024 | clinicalleader.com | Jimmy Bechtel |Stacie Bell |Erin Finot |IQVIA Biotech

Remote Services And Technology Require More Regulatory Clarity For InvestigatorsBy focusing on updating regulatory frameworks, developing technical standards, and leveraging technology for compliance, see how the industry can ensure that digital and remote trials are conducted safely and ethically. Can Optimized Cardiology Trials Solve Major Challenges?

Aug 22, 2024 | clinicalleader.com | Erin Finot |IQVIA Biotech

By Erin Finot, MS, MBA, Vice President, Immuno-Oncology & Cell and Gene Therapy, IQVIA Biotech Designing clinical trials for immuno-oncology (IO) therapies, particularly those involving cell- and gene-based treatments, presents unique scientific and operational challenges. To navigate these complexities, biotech and emerging biopharma companies must adopt strategic approaches tailored to key regulatory and logistical hurdles.

Jul 2, 2024 | clinicalleader.com | Erin Finot |IQVIA Biotech

By Erin Finot, MS, MBA, Vice President, Immuno-Oncology & Cell and Gene Therapy, IQVIA Biotech Gene therapy has surged in the clinical research industry, marked by significant growth and interest. In 2023, venture capital funding reached $3.4 billion, with 406 industry-sponsored clinical trials initiated and 76 cell and gene therapies launched globally.

Jun 21, 2023 | clinicalleader.com | Erin Finot

By Erin Finot, MS, MBA, Vice President, Immuno-Oncology & Cell And Gene Therapy Over the past ten years, the introduction of immuno-oncology (IO) therapies has brought about a revolutionary change in the treatment of cancer patients worldwide. Biotechnology has also played a crucial role in driving translational science, developing therapeutic platforms, and designing new trials to support the progress of IO treatments.